Advances in lung cancer screening and early detection

por Li, Caichen, Wang, Huiting, Jiang, Yu, Fu, Wenhai, Liu, Xiwen, Zhong, Ran, Cheng, Bo, Zhu, Feng, Xiang, Yang, He, Jianxing, Liang, Wenhua
Publicado 2022

The active surveillance management approach for patients with low risk papillary thyroid microcarcinomas: is China ready?

por Liu, Wen, Yan, Xuejing, Cheng, Ruochuan
Publicado 2022

Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling

por Ma, Panpan, Jin, Xinxin, Fan, Zhiwei, Wang, Zhou, Yue, Suhui, Wu, Changyue, Chen, Shiyin, Wu, Yuanyuan, Chen, Miaomiao, Gu, Donghua, Zhang, Siliang, Mao, Renfang, Fan, Yihui
Publicado 2022

PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer

por Liang, Han
Publicado 2022

Immunology and immunotherapy in breast cancer

por Semiglazov, Vladimir, Tseluiko, Andrey, Kudaybergenova, Asel, Artemyeva, Anna, Krivorotko, Petr, Donskih, Roman
Publicado 2022

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era

por Li, Jiakang, Xu, Jingyan, Yang, Mingyi, Zhou, Qing
Publicado 2022

Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population

por Yao, Jianfei, Zhen, Yunhuan, Fan, Jing, Gong, Yuan, Ye, Yumeng, Guo, Shaohua, Liu, Hongyi, Li, Xiaoyun, Li, Guosheng, Yang, Pan, Wang, Xiaohui, Liu, Danni, Huang, Tanxiao, Cao, Huiya, Suo, Peisu, Li, Yuemin, Yu, Jingbo, Song, Lele
Publicado 2022

Targeting the COP9 signalosome for cancer therapy

por Du, Wenqi, Zhang, Ruicheng, Muhammad, Bilal, Pei, Dongsheng
Publicado 2022

Anti-tumor pharmacology of natural products targeting mitosis

por Huang, Manru, Liu, Caiyan, Shao, Yingying, Zhou, Shiyue, Hu, Gaoyong, Yin, Shuangshuang, Pu, Weiling, Yu, Haiyang
Publicado 2022

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma

por Lu, Jia, Li, Ting, Liao, Zhichao, Yu, Hui, Zhao, Yongtian, Wu, Haixiao, Ren, Zhiwu, Zhao, Jun, Xing, Ruwei, Teng, Sheng, Yang, Yun, Li, Xiangchun, Chen, Kexin, Trent, Jonathan, Yang, Jilong
Publicado 2022

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

por Qin, Yan, Chen, Haizhu, Liu, Peng, Zhang, Changgong, Yang, Jianliang, Gui, Lin, He, Xiaohui, Zhou, Liqiang, Zhou, Shengyu, Jiang, Shiyu, Jiang, Hongxin, Shi, Yuankai
Publicado 2022

Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)

por Lee, Sung Uk, Seong, Jinsil, Kim, Tae Hyun, Im, Jung Ho, Kim, Woo Chul, Kim, Kyubo, Park, Hae Jin, Kim, Tae Gyu, Kim, Youngkyong, Jeong, Bae Kwon, Kim, Jin Hee, Kim, Byoung Hyuck, Nam, Taek-Keun
Publicado 2022

Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: a retrospective cohort study

por Liu, Qun, Yin, Qiang, Dong, Yang, Li, Fengtong, Li, Wenliang, Wang, Xiaoguang
Publicado 2022

Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China

por Zhang, Chunli, Wan, Wei, Zhang, Shuai, Wang, Jingwen, Feng, Ru, Li, Jiangtao, Chai, Junyue, Zhou, Hebing, Wang, Liru, Zhong, Yuping, Mo, Xiaodong, Shen, Mengzhu, Jing, Hongmei, Liu, Hui
Publicado 2022

The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families

por Dong, Li, Zhang, Hailian, Zhang, Huan, Ye, Yingnan, Cheng, Yanan, Li, Lijuan, Wei, Lijuan, Han, Lei, Cao, Yandong, Li, Shixia, Hao, Xishan, Liu, Juntian, Yu, Jinpu
Publicado 2022

EHMT2 (G9a) activation in mantle cell lymphoma and its associated DNA methylation and gene expression

por Wang, Jun, Xu, Hui, Ge, Shuang, Xue, Chaoshuai, Li, Hailing, Jing, Xiaotong, Liang, Ke, Zhang, Xiaoying, Zhang, Cuijuan
Publicado 2022

The advanced development of molecular targeted therapy for hepatocellular carcinoma

por Yan, Tao, Yu, Lingxiang, Zhang, Ning, Peng, Caiyun, Su, Guodong, Jing, Yi, Zhang, Linzhi, Wu, Tong, Cheng, Jiamin, Guo, Qian, Shi, Xiaoliang, Lu, Yinying
Publicado 2022

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification

por Li, Jianbin, Jiang, Zefei
Publicado 2022

MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis

por Yan, Fengqi, Wang, Qinhao, Xia, Mingyuan, Ru, Yi, Hu, Wei, Yan, Guang, Xiong, Xin, Zhang, Mei, Wang, Jiancai, Li, Qi, Zhang, Bo, Wang, He, Lin, Wei, Wu, Guojun, Li, Xia
Publicado 2022

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

por Yao, Leyi, Zhao, Qian, Yan, Ding, Lei, Ziying, Hao, Yali, Chen, Jinghong, Xue, Qian, Li, Xiaofen, Huang, Qingtian, Tang, Daolin, Dou, Q. Ping, Chen, Xin, Liu, Jinbao
Publicado 2022